Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium lactis + lactobacillus rhamnosus + bifidobacterium longum ES1 + prebiotic fiber
- Development stage
- Unknown
- Lead developer
- Archer Daniels Midland
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This synbiotic dietary supplement, developed by PronoKal Group in collaboration with Nestlé Health Science, consists of three probiotic bacterial strains—*Bifidobacterium lactis*, *Lactobacillus rhamnosus*, and *Bifidobacterium longum* ES1—paired with a prebiotic fiber. It is specifically designed for use within the PronoKal Method, a weight-loss program centered on a very-low-calorie ketogenic diet (VLCKD). The product functions as a live biotherapeutic, aiming to modulate the gut microbiota to counteract dysbiosis, strengthen the gut barrier, and mitigate systemic inflammation associated with obesity. Its mechanism involves the production of beneficial metabolites like short-chain fatty acids and the competitive exclusion of pathogens, thereby supporting metabolic health during significant dietary transitions.
- Brand names
- PronoKal Synbiotic
- Other names
- PronoKal probiotic-prebiotic combination
Beyond the preview
Go deeper on bifidobacterium lactis + lactobacillus rhamnosus + bifidobacterium longum ES1 + prebiotic fiber.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium lactis + lactobacillus rhamnosus + bifidobacterium longum ES1 + prebiotic fiber.